Exploratory analyses of PIONEER 3 (NCT02607865) assessed the efficacy (HbA1c change from baseline [BL], achievement of HbA1c <7.0%) of oral semaglutide (sema; 3, 7, or 14 mg), a novel oral GLP-1 receptor agonist, vs. sitagliptin (sita) 100 mg at week 26 by BL HbA1c and background OAD in pts with T2D uncontrolled on metformin ± sulfonylurea.

HbA1c was reduced across all BL HbA1c and OAD groups in all treatment arms; reductions were greater with higher BL HbA1c. HbA1c reductions were significantly greater with oral sema 7 and 14 mg vs. sita in all groups, except for 7 mg in the HbA1c ≤8.0% group (Figure 1). Achievement of HbA1c <7.0% was greater with oral sema 7 and 14 mg vs. sita in all groups (Figure 2).

In conclusion, oral sema 7 and 14 mg significantly improved glycemic control vs. sita across most HbA1c groups, and irrespective of background OAD use.

Disclosure

J. Rosenstock: Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline plc., Lexicon Pharmaceuticals, Inc., Melior Pharmaceuticals, Inc., Bukwang Pharm. Co., Ltd., Merck & Co., Inc., Oramed Pharmaceuticals, PegBio Co., Ltd., Pfizer Inc. Other Relationship; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. D.C. Allison: Advisory Panel; Self; Novo Nordisk Inc. Research Support; Self; Bayer US, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Kowa Pharmaceutical Europe Co. Ltd., Sanofi. A.L. Birkenfeld: None. T.M. Blicher: Employee; Self; Novo Nordisk A/S. S. Deenadayalan: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. A. Kousholt: Employee; Self; Novo Nordisk A/S. M.J. Davies: Advisory Panel; Self; Eli Lilly and Company, Janssen Global Services, LLC., Novo Nordisk A/S, Sanofi-Aventis, Servier. Research Support; Self; Boehringer Ingelheim International GmbH, Novo Nordisk Foundation. Speaker’s Bureau; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Sanofi-Aventis, Takeda Pharmaceutical Company Limited.

Funding

Novo Nordisk A/S

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.